Affiliation:
1. Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
2. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
Abstract
Background::
Prostate Stem Cell Antigen (PSCA) is a small cell surface protein, overexpressed
in 90% of prostate cancers. Determination of epitopes that elicit an appropriate response to
the antibody generation is vital for diagnostic and immunotherapeutic purposes for prostate cancer
treatment. Presently, bioinformatics B-cell prediction tools can predict the location of epitopes,
which is uncomplicated, faster, and more cost-effective than experimental methods.
Objective::
We aimed to predict a novel linear peptide for Prostate Stem Cell Antigen (PSCA) protein
in order to generate anti-PSCA-peptide (p) antibody and to investigate its effect on prostate
cancer cells.
Methods::
In the current study, a novel linear peptide for PSCA was predicted using in silico methods
that utilize a set of linear B-cell epitope prediction tools. Polyclonal antibody (anti-PSCA-p
antibody “Patent No. 99318”) against PSCA peptide was generated. The antibody reactivity was determined
by the Enzyme-Linked Immunosorbent Assay (ELISA) and its specificity by immunocytochemistry
(ICC), immunohistochemistry (IHC), and Western Blotting (WB) assays. The effect of
the anti-PSCA-p antibody on PSCA-expressing prostate cancer cell line was assessed by Methylthiazolyldiphenyl-
Tetrazolium bromide (MTT) assay.
Results::
New peptide-fragment of PSCA sequence as “N-CVDDSQDYYVGKKN-C” (PSCA-p)
was selected and synthesized. The anti-PSCA-p antibody against the PSCA-p showed immunoreactivity
with PSCA-p specifically bound to PC-3 cells. Also, the anti-PSCA-p antibody strongly
stained the prostate cancer tissues as compared to Benign Prostatic Hyperplasia (BPH) and normal
tissues (P < 0.001). As the degree of malignancy increased, the staining intensity was also elevated
in prostate cancer tissue (P < 0.001). Interestingly, the anti-PSCA-p antibody showed anti-proliferative
effects on PC-3 cells (31%) with no growth inhibition effect on PSCA-negative cells.
Conclusion::
In this study, we developed a new peptide sequence (PSCA-p) of PSCA. The PSCA-p
targeting by anti-PSCA-p antibody inhibited the proliferation of prostate cancer cells, suggesting
the potential of PSCA-p immunotherapy for future prostate cancer studies.
Funder
Iran University of Medical Sciences
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献